U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H28N2O3
Molecular Weight 392.4907
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of INDACATEROL

SMILES

CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=CC=C(O)C4=C3C=CC(=O)N4

InChI

InChIKey=QZZUEBNBZAPZLX-QFIPXVFZSA-N
InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1

HIDE SMILES / InChI

Description

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.

CNS Activity

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
New approaches to managing asthma: a US perspective.
2008 Apr
Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study.
2008 Dec
Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.
2008 Jul
Gateways to clinical trials.
2008 May
A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors.
2008 Nov-Dec
Gateways to clinical trials.
2008 Oct
Novel long-acting bronchodilators for COPD and asthma.
2008 Oct
Gateways to clinical trials.
2009 Apr
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
2009 Dec
Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder.
2009 Dec
Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?
2009 Dec 8
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
2009 Feb
Gateways to clinical trials.
2009 Jan-Feb
Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
2009 Jul
Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist.
2009 Mar 12
Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma.
2009 May
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol.
2009 Oct
Gateways to clinical trials.
2009 Sep
Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist.
2009 Sep
The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells.
2009 Sep
[Efficacy and safety of indacaterol - new long-acting beta(2) agonist].
2010
Impact of bronchodilator therapy on exercise tolerance in COPD.
2010 Apr 7
Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.
2010 Aug
Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
2010 Dec
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
2010 Dec
Indacaterol once-daily is equally effective dosed in the evening or morning in COPD.
2010 Dec
Indacaterol: in chronic obstructive pulmonary disease.
2010 Dec 3
Novel bronchodilators in asthma.
2010 Jan
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
2010 Jul 15
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
2010 Jun
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
2010 Jun
Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist.
2010 Jun 15
Indacaterol for chronic obstructive pulmonary disease (COPD).
2010 Mar
The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
2010 Mar
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.
2010 Mar 8
The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.
2010 May 13
Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol.
2010 Nov
24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol.
2010 Nov
[Indacaterol is a new once-daily beta2-agonist for treatment of COPD].
2010 Nov 22
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.
2010 Oct 29
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.
2010 Oct 5
Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists.
2010 Sep
Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
2010 Sep
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone.
2010 Sep 7
An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.
2012 Oct 1
Metabolism and pharmacokinetics of indacaterol in humans.
2012 Sep
Emerging Therapeutic Options for the Management of COPD.
2013
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.
2016 Oct
An update on LAMA/LABA combinations for COPD.
2017 Jan
Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
2017 Jan 11
Patents

Sample Use Guides

In Vivo Use Guide
The recommended dosage of Indacaterol is the once-daily inhalation of the contents of one 75 mcg Indacaterol capsule using the NEOHALER inhaler.
Route of Administration: Respiratory
In Vitro Use Guide
In the isolated tracheal strip preparation, indacaterol, demonstrated concentration-dependent inhibition of electrically induced contraction (EC50= 45 ± 13 nM)
Name Type Language
INDACATEROL
INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
QAB149
Code English
INDACATEROL [USAN]
Common Name English
QVA149 COMPONENT INDACATEROL
Common Name English
INDACTEROL
Common Name English
INDACATEROL [VANDF]
Common Name English
INDACATEROL [WHO-DD]
Common Name English
QAB-149
Code English
QVA-149 COMPONENT INDACATEROL
Common Name English
INDACATEROL [MART.]
Common Name English
INDACATEROL [MI]
Common Name English
INDACATEROL [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QR03AC18
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
EMA ASSESSMENT REPORTS XOTERNA BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
EMA ASSESSMENT REPORTS ULTIBRO BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
WHO-ATC R03AC18
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
WHO-ATC R03AL04
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
WHO-VATC QR03AL04
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
Code System Code Type Description
MERCK INDEX
M6240
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY Merck Index
LactMed
312753-06-3
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY
INN
8457
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY
DRUG BANK
DB05039
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY
WIKIPEDIA
INDACATEROL
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY
CAS
312753-06-3
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY
PUBCHEM
6918554
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY SWITZERF
ChEMBL
CHEMBL1095777
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY
RXCUI
1114326
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY RxNorm
IUPHAR
7455
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY
EPA CompTox
312753-06-3
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY
NCI_THESAURUS
C81644
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY
EVMPD
SUB30138
Created by admin on Tue Mar 06 11:22:14 UTC 2018 , Edited by admin on Tue Mar 06 11:22:14 UTC 2018
PRIMARY